In the latest quarter, 7 analysts provided ratings for Evolent Health (NYSE:EVH), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Evolent Health, presenting an average target of $38.29, a high estimate of $45.00, and a low estimate of $31.00. Witnessing a positive shift, the current average has risen by 4.3% from the previous average price target of $36.71.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Evolent Health's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Evolent Health analyst ratings.

All You Need to Know About Evolent Health

Evolent Health: Delving into Financials

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: Evolent Health displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 37.94%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -0.99%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Evolent Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.61%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Evolent Health's ROA excels beyond industry benchmarks, reaching -0.25%. This signifies efficient management of assets and strong financial health.

Debt Management: Evolent Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.6.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.